Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05164289
Other study ID # CHRD 1721
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date December 10, 2021
Est. completion date April 27, 2022

Study information

Verified date May 2022
Source Centre Hospitalier René Dubos
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.


Description:

Since 2015 more and more studies conducted by researchers, especially Dutch and English, are interested in the use of EMDR (Eye Movement Desensitization and Reprocessing) for other pathologies such as bipolar disorder, unipolar depression, anxiety disorders, psychotic disorders, substance use disorders and chronic pain. These studies show that EMDR appears to be a technique that is both effective, capable of significantly improving symptoms, and without risk for patients, while respecting the protocol and the clinical stabilization provided during the procedure. To date, the use of EMDR for the management of psychotic patients has not been the subject of any prospective study in France and the authors' conclusions converge on the fact that it is essential to carry out more research on the subject. For this, the investigators wish to evaluate the effect of EMDR on the management of patients with schizophrenic disorders, on the basis that this psychotherapy would improve their quality of life (improvement of all the specific scores used in psychiatry). : PANSS, DES, HAD and WEMWBS scales). Finally, the investigators believe that it is relevant to assess the benefit of EMDR six months after hospitalization of patients, in order to measure the maintenance of this efficacy in the medium term


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date April 27, 2022
Est. primary completion date April 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years and over, - Hospitalized for decompensated psychotic disorder, Positive diagnosis of schizophrenia or schizoaffective disorder (according to the DSM-V psychiatry manual), - With positive or negative symptoms according to the Positive and Negative Syndrome Scale (PANSS), - Stabilized clinical condition (considered compatible with hospital discharge), - With ambulatory follow-up planned after hospitalization Exclusion Criteria: - < 18 years, - Patients who do not meet the diagnostic criteria (according to the DSM-V psychiatry manual) for schizophrenic or schizoaffective disorder), - Non-French speaking or illiterate patients, - Cognitive disorders making it impossible the understanding and the none- opposition to the study, - Non-stabilized clinical condition (incompatible with hospital discharge),

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control group
Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
EMDR group
Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75

Locations

Country Name City State
France Departement of Psychiatry - Hospital René Dubos Pontoise
France Departement of Psychiatry -Hospital Paul Guiraud Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier René Dubos

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the decrease in the severity of positive or negative symptoms of schizophrenia The decrease in the severity of positive or negative symptoms of schizophrenia is assessed using the "Positive and Negative Syndrome Scale" (PANSS) between M0 and M6.This decrease will be considered effective if it's greater than or equal to 20%. At 6 month after Hospital discharge (M0)
Secondary Assessment of the decrease in the intensity of dissociative symptoms. The decrease in the intensity of dissociative symptoms is assessed using the Dissociative Experience Scale (DES) between M0 and M6.
The DES is a short written questionnaire. It consists of 28 items that assess the frequency of various dissociative symptoms in the patient's daily life.
0 corresponds to the answer "Never" and 100 to the answer "All the time". The total score is obtained by adding the scores of the 28 items and then dividing by 28. This gives a score between 0 and 100.
At 6 month after Hospital discharge (M0)
Secondary Assessment of the decrease in the intensity of anxiety and depressive symptoms. The decrease in the intensity of anxiety and depressive symptoms is assessed using the Hospital Anxiety and Depression (HAD) between M0 and M6 The HAD scale is a short written questionnaire, consisting of 14 items to assess the patient's symptoms of anxiety and depression.
The total anxiety score is obtained by adding the scores of items 1, 3, 5, 7, 9, 11 and 13 and the total depression score by adding the scores of the remaining items.
The interpretation of the results is as follows:
Score = 7 = absence of symptomatology, 8 = Score = 10 = questionable symptomatology Score = 11 = certain symptomatology.
At 6 month after Hospital discharge (M0)
Secondary Quality of life assessment The quality of life is assessed using the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS).
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) assesses the psychological well-being of individuals. It consists of 14 items on a likert scale of 5 (1: never, 2: rarely, 3: sometimes, 4: often, 5: all the time).
In this scale, there is no threshold score, but the higher the score, the stronger the psychological well-being of the individual.
An improvement in the quality of life is measured by an increase in the scale score between M0 and M6
At 6 month after Hospital discharge (M0)
See also
  Status Clinical Trial Phase
Recruiting NCT04608032 - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia N/A
Terminated NCT00660595 - Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose Phase 3
Completed NCT02655172 - Have a Good Grasp of the Worldthe World N/A
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Completed NCT01606436 - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Phase 1
Completed NCT02525315 - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations Phase 2
Completed NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Phase 3
Completed NCT00088491 - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Phase 3
Completed NCT01279213 - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia Phase 4
Completed NCT00600756 - Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Phase 3
Completed NCT00572247 - The Psychiatric Rehabilitation Approach to Weight Loss N/A
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Completed NCT00485823 - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Phase 4
Active, not recruiting NCT00161408 - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia N/A
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Completed NCT00088465 - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder Phase 3
Withdrawn NCT02654405 - Sodium Butyrate For Improving Cognitive Function In Schizophrenia Phase 2/Phase 3
Completed NCT02544516 - Upside Down, Give me the Handle N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2